Denali Therapeutics (DNLI) Is Down 13.9% After First BBB-Crossing Hunter Therapy Wins FDA Nod - What's Changed [Yahoo! Finance]
Denali Therapeutics Inc. (DNLI)
Last denali therapeutics inc. earnings: 8/6 04:30 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.denalitherapeutics.com
Company Research
Source: Yahoo! Finance
therapy for neurologic manifestations of Hunter syndrome in eligible pediatric patients, based on cerebrospinal fluid biomarker reduction and supported by Phase 1/2 data and ongoing confirmatory trials. The approval not only introduces a new treatment option for a rare pediatric neurodegenerative disease, but also validates Denali's TransportVehicle platform as the first transferrin receptor-enabled medicine cleared by the FDA to target both the brain and peripheral tissues. We'll now examine how AVLAYAH's first-in-class blood-brain-barrier-crossing profile and accelerated approval shape Denali Therapeutics' broader investment narrative. Explore 22 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research. What Is Denali Therapeutics' Investment Narrative? To own Denali Therapeutics, you really have to believe that AVLAYAH is more than a one-
Show less
Read more
Impact Snapshot
Event Time:
DNLI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DNLI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DNLI alerts
High impacting Denali Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
DNLI
News
- The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First StepPR Newswire
- Denali Therapeutics (DNLI) had its price target raised by Morgan Stanley from $40.00 to $42.00. They now have an "overweight" rating on the stock.MarketBeat
- Denali Therapeutics (DNLI) had its price target raised by The Goldman Sachs Group, Inc. from $35.00 to $40.00. They now have a "buy" rating on the stock.MarketBeat
- Denali Therapeutics (DNLI) had its price target raised by Stifel Nicolaus from $34.00 to $41.00. They now have a "buy" rating on the stock.MarketBeat
- Denali Therapeutics (DNLI) had its price target raised by BTIG Research from $36.00 to $38.00. They now have a "buy" rating on the stock.MarketBeat
DNLI
Earnings
- 2/26/26 - Beat
DNLI
Sec Filings
- 3/31/26 - Form 8-K
- 3/26/26 - Form SCHEDULE
- 3/25/26 - Form 8-K
- DNLI's page on the SEC website